Leukotriene C4 synthase deficiency

Leukotriene C4 Synthase Deficiency is a rare genetic disorder affecting the body's ability to produce Leukotriene C4 (LTC4), a critical component involved in the inflammatory response. This deficiency is characterized by an impaired production of LTC4 due to mutations in the gene responsible for encoding the enzyme Leukotriene C4 Synthase (LTC4S), which plays a pivotal role in the Leukotriene biosynthesis pathway. Leukotrienes are eicosanoid lipid mediators derived from arachidonic acid, which are essential in mediating various aspects of the inflammatory response, including bronchoconstriction, vascular permeability, and leukocyte recruitment.

Symptoms and Clinical Presentation

Patients with Leukotriene C4 Synthase deficiency may present with a range of symptoms associated with impaired inflammatory response. These can include increased susceptibility to infections, reduced ability to resolve inflammation, and in some cases, symptoms related to Asthma and allergic conditions. However, the clinical presentation can vary significantly among individuals, and some may remain asymptomatic.

Genetics

The condition is caused by mutations in the LTC4S gene located on chromosome 5q35. This gene encodes the enzyme Leukotriene C4 Synthase, which is crucial for the conversion of Leukotriene A4 (LTA4) to Leukotriene C4, a key step in the leukotriene biosynthesis pathway. The inheritance pattern of Leukotriene C4 Synthase deficiency is currently not well-defined due to the rarity of the condition.

Diagnosis

Diagnosis of Leukotriene C4 Synthase deficiency is challenging due to its rarity and the nonspecific nature of its symptoms. It typically involves a combination of clinical evaluation, family history, and specialized laboratory tests that measure leukotriene levels or assess the function of the LTC4S enzyme. Genetic testing may confirm a diagnosis by identifying mutations in the LTC4S gene.

Treatment and Management

There is no specific treatment for Leukotriene C4 Synthase deficiency. Management focuses on symptomatic relief and preventing complications associated with the disorder. This may include the use of anti-inflammatory medications, bronchodilators for patients with asthma-like symptoms, and antibiotics to treat or prevent infections. Regular follow-up with healthcare providers is essential to monitor the condition and adjust treatment as necessary.

Prognosis

The prognosis for individuals with Leukotriene C4 Synthase deficiency varies depending on the severity of symptoms and the presence of associated conditions. With appropriate management, many individuals can lead normal, healthy lives. However, ongoing research is needed to better understand the disorder and develop specific treatments.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian